XML 29 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 27, 2014
Jun. 30, 2015
USD ($)
$ / shares
shares
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
$ / shares
shares
Jun. 30, 2014
USD ($)
shares
Dec. 31, 2014
USD ($)
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock, par value (in dollars per share) | $ / shares   $ 0.01   $ 0.01   $ 0.01
Stock split, conversion ratio 0.0833          
Share-based compensation arrangement by share-based payment award, expiration period       10 years    
Stock-based compensation       $ 322 $ 637  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options   $ 800   $ 800    
Unvested stock options, unrecognized compensation expense weighted average recognition period       1 year 4 months 10 days    
Stock options, granted (in shares) | shares   596,560   608,910 214,296  
Stock options, fair value assumptions, risk free interest rate       1.32%    
Stock options, fair value assumptions, dividend yield       0.00%    
Stock options, fair value assumptions, expected life       4 years 2 months 25 days    
Stock options, fair value assumptions, historical volatility rate       83.00%    
Common stock rights issued (in shares) | shares       1,208,491 115,432  
Deferred revenue   $ 952   $ 952   $ 1,035
Foreign currency translation adjustment   42 $ 22 8 $ 34 (50)
Foreign currency transaction loss, realized (less than)       $ 100 $ 100  
Options, warrants and conversion rights, common stock callable and antidilutive (in shares) | shares       8,286,963 5,510,255  
Accumulated Other Comprehensive Income            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Foreign currency translation adjustment       $ 8 $ 34 (50)
Pharmacogenomic Services            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue   100   100   100
Diagnostic Tools            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue   $ 800   $ 800   $ 700
Executive Officers            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       3 years    
Common stock rights issued (in shares) | shares       98,333    
Selling, General and Administrative Expenses            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation       $ 300 $ 600  
Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       3 years